financetom
Business
financetom
/
Business
/
Manchester United Sees Fiscal 2024 Revenue at Higher End of Guidance; Third-Quarter Sales Tumble
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Manchester United Sees Fiscal 2024 Revenue at Higher End of Guidance; Third-Quarter Sales Tumble
Jul 10, 2024 8:09 AM

10:59 AM EDT, 07/10/2024 (MT Newswires) -- Manchester United ( MANU ) said Wednesday that it expects full-year revenue to come in at the higher end of its prior guidance despite reporting double-digit declines in two of its three reportable segments in the fiscal third quarter.

The British soccer franchise projects record revenue of 660 million British pounds ($847.1 million) in fiscal 2024, compared with its previous 635 million pounds to 665 million pounds range. Three analysts surveyed by Capital IQ are modeling for revenue of 652.3 million pounds in the ongoing year.

The company forecasts full-year adjusted earnings before interest, taxes, depreciation and amortization at 140 million pounds, toward the higher end of its earlier guidance between 125 million pounds and 150 million pounds.

Shares of Manchester United ( MANU ) rose 3.2% in Wednesday trade.

For the fiscal third quarter, revenue declined 20% year over year to 136.7 million pounds. The company's adjusted loss per share grew 230% to 0.24 pounds for the three months ended March 31.

Broadcasting revenue dropped 26% to 37.5 million pounds due to the men's first team playing in fewer matches. Matchday revenue plummeted 41% to 29.6 million pounds amid nine fewer home matches.

Commercial revenue ticked up 0.3% to 69.6 million pounds, driven by retail, merchandise, apparel and product licensing.

Manchester United's ( MANU ) operating expenses ballooned 15% year over year to 203.7 million pounds.

Price: 16.46, Change: +0.52, Percent Change: +3.26

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Integrated Rail And Resources Acquisition Corp. Announces Extension
BRIEF-Integrated Rail And Resources Acquisition Corp. Announces Extension
Jun 12, 2024
Integrated Rail and Resources Acquisition Corp ( IRRX ): * INTEGRATED RAIL AND RESOURCES ACQUISITION CORP. ( IRRX ) ANNOUNCES EXTENSION * INTEGRATED RAIL AND RESOURCES ACQUISITION ( IRRX )- INTENDS TO EXTEND TIME AVAILABLE IN ORDER TO CONSUMMATE A BUSINESS COMBINATION TO JULY 15, 2024 Source text for Eikon: Further company coverage: ...
Barinthus Bio to Cut Workforce 25% to Focus on Hepatitis, Celiac Treatments After Positive Data; Shares Rise After Hours
Barinthus Bio to Cut Workforce 25% to Focus on Hepatitis, Celiac Treatments After Positive Data; Shares Rise After Hours
Jun 12, 2024
06:19 PM EDT, 06/12/2024 (MT Newswires) -- Barinthus Biotherapeutics ( BRNS ) plans to cut 25% of its workforce to focus on development of VTP-300 for chronic Hepatitis B and VTP-1000 for celiac disease following positive interim data from trials. The pipeline prioritization is expected to extend the cash runway into Q2 2026, the company said late Wednesday in a...
Samsung offers plan to speed up delivery of AI chips
Samsung offers plan to speed up delivery of AI chips
Jun 12, 2024
SEOUL/SAN JOSE, June 12 (Reuters) - Samsung Electronics ( SSNLF ) said its contract manufacturing business plans to offer a one-stop shop for clients to get their AI chips made faster, integrating its global No. 1 memory chip, foundry, and chip packaging services, to harness the AI boom. With clients working with a single channel of communication that directs Samsung's...
Pfizer's Duchenne gene therapy fails in late-stage study
Pfizer's Duchenne gene therapy fails in late-stage study
Jun 12, 2024
June 12 (Reuters) - Pfizer ( PFE ) said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy (DMD) failed to improve the motion function of patients in a late-stage trial compared with a placebo. The therapy also did not show a significant difference compared to placebo in secondary goals of the study such the time it takes for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved